Acute Neuroform Stenting of a Symptomatic Petrous Dissection
CASE REPORTS:
Acute Neuroform Stenting of a Symptomatic Petrous Dissection
- a,b,dRobert D. Ecker, MD, a,b,c,dElad I. Levy, MD, a,b,c,dL. Nelson Hopkins, MD
| | |
ABSTRACT: The authors describe the case of a 51-year-old male who presented with an acute left petrous carotid dissection with neuroimaging evidence of decreased perfusion. Revascularization was accomplished with the placement of an intracranial stent (Neuroform III, Boston Scientific Corp., Natick, Massachusetts). The patient had a good clinical and radiographic outcome.
Only two therapies for acute stroke intervention have been approved by the U.S. Food and Drug Administration:Figure 1
|  | | (A) Computed tomographic perfusion image shows increased time-to-peak in the distribution of the left intracranial carotid artery (arrow). (B) Lateral digital subtraction angiogram demonstrates flow-limiting petrous dissection (upper arrow) and 360-degree proximal loop (lower arrow). (C) Lateral digital subtraction angiogram after placement of 4.5 x 30 mm Neuroform III stent with good revascularization, but persistence of a small flap. Arrows indicate the extent of the stent. (D) Lateral digital subtraction angiogram after balloon angioplasty shows complete revascularization (arrow). (E,F) Hyperintensity (arrows) in diffusion-weighted magnetic resonance images demonstrates watershed-type infarction in the anterior cerebral artery and middle cerebral artery. | intravenous tissue plasminogen activator (tPA) and the Merci retriever (Concentric Medical, Mountainview, California). Many patients fall outside the therapeutic window for tPA administration, and the benefit is marginal.1 When used alone, the Merci device is unsuccessful in approximately 35–50% of patients.2,3 Additionally, neuroimaging techniques and criteria to select optimum candidates for acute intervention have not been developed. We report a case in which a self-expanding stent designed for wide-necked aneurysm treatment was used to revascularize an acute symptomatic petrous carotid dissection. Case Study. A 51-year-old hypertensive male developed a severe headache, right-sided hemiplegia, complete facial palsy and mutism. After evaluation at an outside emergency room, he was flown to our institution. On arrival, his deficits had been fixed for 5 hours, and his National Institutes of Health Stroke Scale score was 16. Computed tomographic perfusion imaging documented increased time-to-peak in the carotid territory, without evidence of a completed stroke (Figure 1A). After informed consent had been obtained from the patient, angiography and endovascular treatment were performed on an urgent basis. Angiography revealed a 360-degree turn and flow-limiting left petrous dissection (Figure 1B). An 0.018-inch Nautica microcatheter (ev3, Inc., Plymouth, Minnesota) and a gold-tip glide wire were used to cross the dissection into the normal distal lumen. A microcatheter run confirmed patency of the artery without significant clot burden. A 300 cm Transcend exchange wire (Boston Scientific Corp., Natick, Massachusetts) was placed into the cavernous internal carotid artery, and the microcatheter exchanged out. This wire was then used as the rail for stenting. Because of the tight proximal loop and extension of the dissection over a curve, we used a 4.5 x 30 mm Neuroform III stent (Boston Scientific), which was deployed easily across the lesion. A small residual flap was dilated with a 5 x 20 mm Aviator balloon (Cordis Endovascular, Miami, Florida), resulting in complete revascularization (Figures 1C and D). Immediately after stent deployment, a bolus dose of eptifibatide and a loading dose of clopidogrel (450 mg) were administered. During the next 48 hours, the patient regained normal strength on the right side with only a mild drift, and his speech returned, although he had significant difficulty with phonation. Follow-up magnetic resonance imaging demonstrated patchy infarctions in the territories of the anterior cerebral and middle cerebral arteries (Figures 1E and F). At the time of discharge, the patient’s National Institutes of Health Stroke Scale score was 5. Acknowledgment. We thank Paul H. Dressel for preparation of the illustrations. |
References- Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145–1150.
- Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: A phase 1 study of mechanical embolus removal in cerebral ischemia. Stroke 2004;35:2848–2854.
- Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke 2005;36:1432–1438.
|
| The Journal of Invasive Cardiology - ISSN: 1042-3931 - Volume 19 - Issue 5 - May 2007 - Pages: E137 - E138 | |
|
Create a Successful Vena Cava Filter Practice
Accredited CD
This activity is supported by an educational grant from Cook Incorporated and has been designed for Interventional Cardiologists, Vascular Surgeons, Fellows and Interventional Cardiovascular Nurses and Technologists.
|
| |
|
|
|
|
Achieving Optimal Outcomes in Carotid Stenting: Lessons Learned from Recent Clinical Trials
Complimentary Accredited ON DEMAND Webcast
Topics
1. EVA-3S & Space-Bumps in the road
2. CAPTURE 3500-Lesion morphology & Predictors for Stroke
3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease. |
|
Anticoagulation Techniques for Peripheral Vascular Interventions
Complimentary Accredited ON DEMAND Webcast
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Podiatric Physicians, Endovascular Allied Professionals, Endocrinologists, Wound Care Specialists, Directors of the Wound Care Clinic, and Primary Care Physicians, Pharmacists, Nurses and Technologists.
|
|
|
|
|
|
March 2007 Supplement
|
On-Demand Webcast
|
Archived Webcast
|
|
|
|
|
|
About HMP Communications
HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications |
© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd, Suite 100 | Malvern, PA 19355 | 800.237.7285
|
|
| | |